Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection (Q38570500)

4 September 2017

Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection (English)

1 reference

4 September 2017

Tae Eun Park

1

1 reference

4 September 2017

Abdilahi Mohamed

series ordinal

2

1 reference

4 September 2017

Julie Kalabalik

series ordinal

3

1 reference

4 September 2017

Roopali Sharma

series ordinal

4

1 reference

4 September 2017

10 August 2015

1 reference

Expert Review of Anti-infective Therapy

4 September 2017

1 reference

4 September 2017

13

1 reference

4 September 2017

10

1 reference

4 September 2017

1195-1212

1 reference

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease

4 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Prevention of HIV-1 infection with early antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Exacerbation of depression associated with starting raltegravir: a report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 result

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Is resistance to dolutegravir possible when this drug is used in first-line therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 w

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1075393

10.1586/14787210.2015.1075393

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference